William Blair Investment Management LLC Acquires 13,174 Shares of Glaukos Corporation $GKOS

William Blair Investment Management LLC boosted its holdings in shares of Glaukos Corporation (NYSE:GKOS) by 1.2% during the fourth quarter, HoldingsChannel reports. The fund owned 1,106,918 shares of the medical instruments supplier’s stock after purchasing an additional 13,174 shares during the quarter. William Blair Investment Management LLC’s holdings in Glaukos were worth $124,982,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in GKOS. UMB Bank n.a. grew its holdings in Glaukos by 102.6% during the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 158 shares during the last quarter. First Horizon Corp grew its holdings in Glaukos by 1,715.4% during the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 223 shares during the last quarter. Larson Financial Group LLC grew its holdings in Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 132 shares during the last quarter. REAP Financial Group LLC bought a new stake in Glaukos during the 3rd quarter worth approximately $40,000. Finally, Farther Finance Advisors LLC grew its holdings in Glaukos by 111.4% during the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock worth $46,000 after acquiring an additional 215 shares during the last quarter. 99.04% of the stock is owned by institutional investors.

Insider Activity

In other news, COO Joseph E. Gilliam sold 19,573 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $143.54, for a total value of $2,809,508.42. Following the sale, the chief operating officer directly owned 73,419 shares of the company’s stock, valued at approximately $10,538,563.26. This represents a 21.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Alex R. Thurman sold 10,000 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $140.00, for a total transaction of $1,400,000.00. Following the transaction, the chief financial officer directly owned 43,681 shares in the company, valued at approximately $6,115,340. This represents a 18.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 45,930 shares of company stock valued at $6,321,363. Company insiders own 5.90% of the company’s stock.

Glaukos Trading Down 13.0%

NYSE:GKOS opened at $120.95 on Friday. The firm’s fifty day moving average is $120.19 and its 200-day moving average is $113.34. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.43. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $148.11. The firm has a market cap of $7.10 billion, a P/E ratio of -36.88 and a beta of 0.94.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The company had revenue of $150.57 million for the quarter, compared to analyst estimates of $137.00 million. During the same period in the prior year, the firm posted ($0.22) EPS. The company’s quarterly revenue was up 41.2% on a year-over-year basis. Equities analysts expect that Glaukos Corporation will post -0.57 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on GKOS shares. Wells Fargo & Company boosted their target price on shares of Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. William Blair raised shares of Glaukos to a “strong-buy” rating in a report on Friday, January 30th. Citigroup boosted their target price on shares of Glaukos from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Stifel Nicolaus set a $170.00 price objective on shares of Glaukos in a research note on Thursday, April 30th. Finally, Wall Street Zen raised shares of Glaukos from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $146.17.

Trending Headlines about Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Wall Street analyst commentary was still constructive overall, with BTIG reiterating a Buy rating and setting a $162 price target, while other firms also maintained bullish views. Article: Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure
• Positive Sentiment: Zacks Research raised some near-term and longer-term earnings estimates for Glaukos, suggesting analysts still see improving profitability over time. Article: Glaukos Corporation analyst updates
• Neutral Sentiment: Recent quarterly results were stronger than expected, with Glaukos beating EPS and revenue estimates and reporting 41% year-over-year revenue growth, which helped fuel the earlier rally. Article: Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure
• Neutral Sentiment: The stock’s recent rise also came after management lifted its 2026 sales outlook, leaving shares vulnerable to a short-term reset if momentum cooled. Article: Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure
• Negative Sentiment: Recent insider-sale filings, including a CFO stock sale under a pre-arranged trading plan, added to near-term selling pressure and may have amplified concerns about insider sentiment. Article: Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.